The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L.
Molinelli C, et al. Among authors: lanzavecchia c.
Eur J Cancer. 2024 Nov 4;213:115113. doi: 10.1016/j.ejca.2024.115113. Online ahead of print.
Eur J Cancer. 2024.
PMID: 39536433
Free article.